Ethan B. Ludmir, MD, explains why advanced radiation techniques like protons fit nonoperative cholangiocarcinoma better than ...

In a phase 1 first-in-human trial, BMS-986453 showed a favorable safety profile and high response rates in ...

Ayal Aizer, MD, MHS, discusses patients for whom single-fraction SRS may remain reasonable after brain metastasis resection.

The faculty then trace the development history of belantamab mafodotin. They describe the landscape around 2018, when daratumumab as a single agent produced a response rate close to 30% and only naked ...

Following the FDA approval of lirafugratinib (Lyrfigtu) for previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma, there are currently 3 FGFR2 inhibi ...

The phase 3 NRG-GI003 trial showed no overall survival benefit with proton therapy over photon therapy in patients with advanced hepatocellular carcinoma.

“It should be protocol that 100% of your patients with metastatic prostate cancer get germline testing. Full stop. No exceptions,” said Neal D. Shore, MD, FACS.

In the phase 3 NRG-CC009 trial, SRS led to longer overall survival vs HA-WBRT plus memantine with similar neurocognitive failure in SCLC brain metastases.

Chih-Yi “Andy” Liao, MD, discusses the FDA approval of lirafugratinib and what the field has learned about resistance to FGFR2 inhibitors.

In a secondary analysis of the DEPROMP trial, 94.8% of biopsy-naive men had no AEs immediately after multimodal MRI- and PSMA ...

Estelamari Rodriguez, MD, MPH, of Sylvester Comprehensive Cancer Center presents the final overall survival data from the phase 3 FLAURA2 study of osimertinib plus chemotherapy in epidermal growth ...

Ethan B. Ludmir, MD, explains the rationale for moving radiation into the neoadjuvant setting for borderline resectable ...